The risks and incidence of K65R and L74V mutations and subsequent virologic responses.
The L74V and K65R mutations confer resistance to several nucleoside analogues, and the impact on subsequent regimens is unclear. The risk of developing L74V or K65R mutation in the era of highly active antiretroviral therapy (HAART) was 4.5 and 2.8 cases per 100 person-years, respectively; concomitant receipt of boosted protease inhibitors protected against K65R. High rates of virologic suppression in the presence of either mutation were observed if the next regimen contained at least 2 active agents. If suboptimal HAART was used, patients with K65R experienced significantly higher rates of virologic suppression than did those with L74V (P = .01).
Waters
Laura
L
Department of HIV Medicine, Chelsea and Westminster Hospital and Imperial College School of Medicine, London, United Kingdom.
Nelson
Mark
M
Mandalia
Sundhiya
S
Bower
Mark
M
Powles
Tom
T
Gazzard
Brian
B
Stebbing
Justin
J
D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D024921:Drug Resistance, Multiple, Viral; D020022:Genetic Predisposition to Disease; D006678:HIV / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D006801:Humans; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D019562:Viral Load
D044966:Anti-Retroviral Agents; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase